{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:11:51Z","timestamp":1698318711301},"reference-count":53,"publisher":"Akademiai Kiado Zrt.","issue":"11","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,3,13]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A kr\u00f3nikus autoimmun betegs\u00e9gben szenved\u0151kben a s\u00falyos\n                    COVID\u201319 kialakul\u00e1s\u00e1nak kock\u00e1zata magasabb, a SARS-CoV-2-fert\u0151z\u00e9s pedig a\n                    kr\u00f3nikus alapbetegs\u00e9g progresszi\u00f3j\u00e1hoz, fell\u00e1ngol\u00e1s\u00e1hoz vezethet. A COVID\u201319\n                    elker\u00fcl\u00e9s\u00e9nek legbiztons\u00e1gosabb, legk\u00f6lts\u00e9ghat\u00e9konyabb m\u00f3dszere a vakcin\u00e1ci\u00f3,\n                    illetve az emellett alkalmazott higi\u00e9n\u00e9s szab\u00e1lyok betart\u00e1sa, a megfelel\u0151 maszk\n                    visel\u00e9se. A hiedelemmel ellent\u00e9tben \u00f6nmag\u00e1ban az autoimmun megbeteged\u00e9s nem\n                    jelent olt\u00e1si ellenjavallatot, s\u0151t a rizik\u00f3\u00e1llapot miatt ezek a betegek az els\u0151k\n                    k\u00f6z\u00f6tt oltand\u00f3k. A COVID\u201319 elleni vakcina alkalmaz\u00e1s\u00e1nak egyetlen egy\u00e9rtelm\u0171\n                    kontraindik\u00e1ci\u00f3ja az anamn\u00e9zisben szerepl\u0151 s\u00falyos allergi\u00e1s reakci\u00f3 (anafilaxia)\n                    a vakcina valamelyik alkot\u00f3r\u00e9sz\u00e9vel szemben. A betegek olthat\u00f3s\u00e1g\u00e1t t\u00f6bbek\n                    k\u00f6z\u00f6tt befoly\u00e1solja az aktu\u00e1lis betegs\u00e9gaktivit\u00e1s \u00e9s az alkalmazott kezel\u00e9s. Az\n                    immuniz\u00e1ci\u00f3 idej\u00e9t a legbiztons\u00e1gosabban a gondoz\u00f3 orvos tervezheti meg. Az\n                    autoimmun betegek immuniz\u00e1ci\u00f3ja sor\u00e1n \u00e9szlelhet\u0151 olt\u00e1si reakci\u00f3k \u00e9s sz\u00f6v\u0151dm\u00e9nyek\n                    incidenci\u00e1ja megegyezik az eg\u00e9szs\u00e9ges popul\u00e1ci\u00f3ban is tapasztalt el\u0151fordul\u00e1si\n                    gyakoris\u00e1ggal. Orv Hetil. 2022; 163(11): 414\u2013423.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> The risk of developing severe COVID\u201319 is higher in\n                    patients with autoimmune diseases, and SARS-CoV-2 infection can lead to\n                    progression and exacerbation of the underlying chronic disease. The safest and\n                    most cost-effective way to avoid COVID\u201319 is to be vaccinated, to follow the\n                    hygiene rules and to wear an appropriate mask. Contrary to belief, autoimmune\n                    disease alone is not a contraindication to vaccination and, in fact, patients\n                    should be among the first to be vaccinated because of the risk. The only clear\n                    contraindication to the use of COVID\u201319 vaccine is a history of severe allergic\n                    reaction (anaphylaxis) to any of the components of the vaccine. Indication of\n                    vaccination migh be influenced by, among other things, the current disease\n                    activity and the treatment applied. The timing of immunization can be the most\n                    safely planned by the attending physician. The incidence of vaccination\n                    reactions and complications during immunization in autoimmune patients is\n                    similar to that seen in the healthy population. Orv Hetil. 2022; 163(11):\n                    414\u2013423.<\/jats:p>","DOI":"10.1556\/650.2022.32448","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:50:55Z","timestamp":1668765055000},"page":"414-423","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2-fert\u0151z\u00e9s \u00e9s annak megel\u0151z\u00e9se gyermekkori kr\u00f3nikus sziszt\u00e9m\u00e1s autoimmun betegs\u00e9gekben"],"prefix":"10.1556","volume":"163","author":[{"given":"Tam\u00e1s","family":"Constantin","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, II. Gyermekgy\u00f3gy\u00e1szati Klinika Budapest, T\u0171zolt\u00f3 u. 7\u20139., 1094 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kulcs\u00e1r","sequence":"additional","affiliation":[{"name":"D\u00e9l-pesti Centrumk\u00f3rh\u00e1z \u2013 Orsz\u00e1gos Hematol\u00f3giai \u00e9s Infektol\u00f3giai Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Kriv\u00e1csy","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, I. Gyermekgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"M\u00e9szner","sequence":"additional","affiliation":[{"name":"Heim P\u00e1l Orsz\u00e1gos Gyermekgy\u00f3gy\u00e1szati Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ponyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, II. Gyermekgy\u00f3gy\u00e1szati Klinika Budapest, T\u0171zolt\u00f3 u. 7\u20139., 1094 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, V\u00e1rosmajori Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Be\u00e1ta","family":"\u00d3noz\u00f3","sequence":"additional","affiliation":[{"name":"Borsod-Aba\u00faj-Zempl\u00e9n Megyei K\u00f6zponti K\u00f3rh\u00e1z \u00e9s Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Velkey L\u00e1szl\u00f3 Gyermekeg\u00e9szs\u00e9g\u00fcgyi K\u00f6zpont Miskolc Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[{"name":"Debreceni Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Reumatol\u00f3giai Tansz\u00e9k Debrecen Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Medrxiv 2021; 2021.09.15.21263583.","DOI":"10.1101\/2021.09.15.21263583"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"2 Tartof","year":"2021","unstructured":"2 Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398: 1407-1416.","journal-title":"Lancet"},{"key":"ref2","unstructured":"3 Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv preprint 2021; 2021.10.26.21265397."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Rosenberg ES, Dorabawila V, Easton D, et al. COVID-19 Vaccine effectiveness by product and timing in New York State. medRxiv 2021; 2021.10.08.21264595.","DOI":"10.1101\/2021.10.08.21264595"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"5 Bar-On","year":"2021","unstructured":"5 Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021; 385: 1393-1400.","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","volume":"80","author":"6 Akiyama","year":"2021","unstructured":"6 Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021; 80: 384-391.","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Case series from New York","volume":"383","author":"7 Haberman","year":"2020","unstructured":"7 Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases. Case series from New York. N Engl J Med. 2020; 383: 85-88.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'","volume":"79","author":"8 D'Silva","year":"2020","unstructured":"8 D'Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020; 79: 1156-1162.","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/annrheumdis-2020-217763","article-title":"Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases","volume":"79","author":"9 Pablos","year":"2020","unstructured":"9 Pablos JL, Abasolo L, Alvaro-Gracia JM, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020; 79: 1170-1173.","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10 Jovani V, Calabuig I, Peral-Garrido ML, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020 Jun 25. . [Epub ahead of print]","DOI":"10.1136\/annrheumdis-2020-218152"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology 2021; 60(SI): SI59-SI67.","DOI":"10.1093\/rheumatology\/keaa897"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/BOR.0000000000000725","article-title":"Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases","volume":"32","author":"12 Gianfrancesco","year":"2020","unstructured":"12 Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol. 2020; 32: 434-440.","journal-title":"Curr Opin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.trsl.2020.12.007","article-title":"COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease","volume":"232","author":"13 Fernandez-Ruiz","year":"2021","unstructured":"13 Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res. 2021; 232: 13-36.","journal-title":"Transl Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"14 Strangfeld","year":"2021","unstructured":"14 Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80: 930-942.","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheumatol. 2021; 73: e1-e12.","DOI":"10.1002\/art.41596"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16 Machado PM, Lawson-Tovey S, Strangfeld A, et al. Covid-19 vaccine safety in patients with rheumatic and musculoskeletal disease. Ann Rheum Dis. 2021 Dec 31. . [Epub ahead of print]","DOI":"10.1136\/annrheumdis-2021-eular.5097"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021; 7: e001814.","DOI":"10.1136\/rmdopen-2021-001814"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"18 Furer","year":"2021","unstructured":"18 Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021; 80: 1330-1338.","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"19 Braun-Moscovici","year":"2021","unstructured":"19 Braun-Moscovici Y, Kaplan M, Braun M, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021; 80: 1317-1321.","journal-title":"Ann Rheum Dis"},{"key":"ref19","unstructured":"20 Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with Covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020; 370: m3249."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.15585\/mmwr.mm6939e2","article-title":"COVID-19 trends among school-aged children - United States, March 1-September 19, 2020","volume":"69","author":"21 Leeb","year":"2020","unstructured":"21 Leeb RT, Price S, Sliwa S, et al. COVID-19 trends among school-aged children - United States, March 1-September 19, 2020. Morb Mortal Wkly Rep. 2020; 69: 1410-1415.","journal-title":"Morb Mortal Wkly Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamapediatrics.2020.1467","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review","volume":"174","author":"22 Castagnoli","year":"2020","unstructured":"22 Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020; 174: 882-889.","journal-title":"JAMA Pediatr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study","volume":"4","author":"23 G\u00f6tzinger","year":"2020","unstructured":"23 G\u00f6tzinger F, Santiago-Garc\u00eda B, Noguera-Juli\u00e1n A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; 4: 653-661.","journal-title":"Lancet Child Adolesc Health"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC Metropolitan Region. J Pediatrics 2020; 223: 199-203.e1.","DOI":"10.1016\/j.jpeds.2020.05.007"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/jamapediatrics.2020.1948","article-title":"Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units","volume":"174","author":"25 Shekerdemian","year":"2020","unstructured":"25 Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020; 174: 868-873.","journal-title":"JAMA Pediatr"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Fernandes DM, Oliveira CR, Guerguis S, et al. SARS-CoV-2 clinical syndromes and predictors of disease severity in hospitalized children and youth. J Pediatr. 2021; 230: 23-31.e10.","DOI":"10.1016\/j.jpeds.2020.11.016"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27 Constantin T, Andr\u00e1si N, Ponyi A, et al. Diagnosis and treatment of paediatric inflammatory multisystem syndrome. [A gyermekkori koronav\u00edrus-fert\u0151z\u00e9st k\u00f6vet\u0151 sokszervi gyullad\u00e1s diagnosztik\u00e1ja \u00e9s kezel\u00e9se.] Orv Hetil. 2021; 162: 652-667. [Hungarian]","DOI":"10.1556\/650.2021.32231"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/apa.15870","article-title":"Preliminary evidence on long COVID in children","volume":"110","author":"28 Buonsenso","year":"2021","unstructured":"28 Buonsenso D, Munblit D, Rose CD, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021; 110: 2208-2211.","journal-title":"Acta Paediatr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/apa.15673","article-title":"Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19","volume":"110","author":"29 Ludvigsson","year":"2021","unstructured":"29 Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021; 110: 914-921.","journal-title":"Acta Paediatr"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 Funk AL, Florin TA, Dalziel SR, et al. Prospective cohort study of children with suspected SARS-CoV-2 infection presenting to paediatric emergency departments: a Paediatric Emergency Research Networks (PERN) Study Protocol. BMJ Open 2021; 11: e042121.","DOI":"10.1136\/bmjopen-2020-042121"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/camh.12428","article-title":"Debate: the impact of school closures and lockdown on mental health in young people","volume":"25","author":"31 Townsend","year":"2020","unstructured":"31 Townsend E. Debate: the impact of school closures and lockdown on mental health in young people. Child Adolesc Ment Health 2020; 25: 265-266.","journal-title":"Child Adolesc Ment Health"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32 Sengler C, Eulert S, Minden K, et al. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open 2021; 7: e001687.","DOI":"10.1136\/rmdopen-2021-001687"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33 Sozeri B, Ulu K, Kaya-Ak\u00e7a U, et al. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatol Int. 2021 Sep 27; 1-7. . [Epub ahead of print]","DOI":"10.1007\/s00296-021-05008-w"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"34 Dagan","year":"2021","unstructured":"34 Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384: 1412-1423.","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck RW Jr","year":"2021","unstructured":"35 Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021; 385: 239-250.","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"36 Ali","year":"2021","unstructured":"36 Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021; 385: 2241-2251.","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMc2114290","article-title":"Effectiveness of BNT162b2 vaccine against delta variant in adolescents","volume":"385","author":"37 Reis","year":"2021","unstructured":"37 Reis BY, Barda N, Leshchinsky M, et al. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. N Engl J Med. 2021; 385: 2101-2103.","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38 Lopez Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med; 2021; 385: 585-594.","DOI":"10.1056\/NEJMoa2108891"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39 Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis. 2022; 74: 59-65.","DOI":"10.1093\/cid\/ciab229"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41591-021-01316-7","article-title":"Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine","volume":"27","author":"40 Levine-Tiefenbrun","year":"2021","unstructured":"40 Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med; 2021; 27: 790-792.","journal-title":"Nat Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"41 Walter","year":"2022","unstructured":"41 Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022; 386: 35-46.","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42 Goldman E. How the unvaccinated threaten the vaccinated for COVID-19: a Darwinian perspective. Proc Natl Acad Sci. 2021; 118: e2114279118.","DOI":"10.1073\/pnas.2114279118"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43 Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021; 385: e85.","DOI":"10.1056\/NEJMoa2114228"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44 Snapiri O, Rosenberg Danziger C, Shirman N, et al. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine. Pediatr Infect Dis J. 2021; 40: e360-e363.","DOI":"10.1097\/INF.0000000000003235"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"45 Barda","year":"2021","unstructured":"45 Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021; 385: 1078-1090.","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization","volume":"385","author":"46 Witberg","year":"2021","unstructured":"46 Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021; 385: 2132-2139.","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021","volume":"70","author":"47 Gargano","year":"2021","unstructured":"47 Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021. Morb Mortal Wkly Rep. 2021; 70: 977-982.","journal-title":"Morb Mortal Wkly Rep"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48 Haaf P, Kuster GM, Mueller C, et al. The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly 2021; 151: w30087.","DOI":"10.4414\/SMW.2021.w30087"},{"key":"ref48","unstructured":"49 COVID-19 Greenbook chapter 14a. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1045852\/Greenbook-chapter-14a-11Jan22.pdf [accessed: February 14, 2022]"},{"key":"ref49","unstructured":"50 CDC Recommends Pfizer Booster at 5 Months, Additional Primary Dose for Certain Immunocompromised Children | CDC Online Newsroom | CDC. Available from: https:\/\/www.cdc.gov\/media\/releases\/2022\/s0104-Pfizer-Booster.html [accessed: February 14, 2022]"},{"key":"ref50","unstructured":"51 CDC Expands Booster Shot Eligibility and Strengthens Recommendations for 12-17 Year Olds | CDC Online Newsroom | CDC. Available from: https:\/\/www.cdc.gov\/media\/releases\/2022\/s0105-Booster-Shot.html [accessed: February 14, 2022]"},{"key":"ref51","unstructured":"52 Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html [accessed: February 15, 2022]"},{"key":"ref52","unstructured":"53 Professional recommendation for vaccination against COVID-19. [Szakmai javaslat a COVID-19 elleni v\u00e9d\u0151olt\u00e1sok alkalmaz\u00e1s\u00e1hoz.] Available from: https:\/\/www.nnk.gov.hu\/attachments\/article\/1358\/szakmai%20aj%C3%A1nl%C3%A1s%20COVID-19%20v%C3%A9d%C5%91olt%C3%A1sok%20alkalmaz%C3%A1s%C3%A1hoz%2001.14.pdf [accessed: February 14, 2022] [Hungarian]"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/11\/article-p414.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/11\/article-p414.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/11\/article-p414.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T13:51:11Z","timestamp":1698241871000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/11\/article-p414.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,13]]},"references-count":53,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32448","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,13]]}}}